07/27/2022
Alert shared by Drug Abuse Issues Coalition C.C.TX. .... The Canadian Community Epidemiology Network on Drug Use (CCENDU) and U.S. National Drug Early Warning System (NDEWS) have identified an increase in xylazine, a non-opioid sedative and muscle relaxant, prompting an alert released today. Highlights:
In 2021, 31% of 398 opioid samples tested statewide contained
xylazine. As of June 15, xylazine was detected in 28% of 263 opioid samples
tested in 2022.
Use experiences noted “made me sleep weird”; “put me out for 6 hours”;
“very strong”; “made me pass out and I woke with vomit on me”, “skin on
fire, teeth felt like they were going to fall out”, and “causing holes
(ulcers) where injected”.
We see an increased prevalence of xylazine in the western part of the
state vs. the eastern part of the state. WBUR, a local public radio
station, aired this piece
https://www.wbur.org/news/2022/07/15/xylazine-an-animal-tranquilizer-compounds-overdose-crisisthat
covers both one of our MADDS sites and some of the experiences of people
and programs in beautiful Greeenfield, Massachusetts in the western part of
the state
All alerts contain resources and suggestions from the
Massachusetts Department of Health Bureau of Substance Addiction Services,
our scientific advisors, and our community consumer advisory board, which
include* increasing awareness, reducing harm, and facilitating care* for
the broad range of xylazine-related health and safety challenges that
people may experience with increasing xylazine presence in the drug supply. https://network.cesaresearch.org/t/ccendu-alert-xylazine-heightens-overdose-risk/9363?u=akt56turner
Center for Substance Abuse Research (CESAR), University of Maryland, College Park